Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
NAD+Small moleculeNo amino acid sequence. Icon reflects category theme only.Also known as: NAD, NAD+, Coenzyme I
Plasma NAD+ levels jumped 398% above baseline after a single six-hour IV infusion in a 2019 pilot study [1]. NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in every living cell, powering over 500 enzymatic reactions tied to energy production, DNA repair, and sirtuin activation. The catch: controlled human trial data for general anti-aging use remains thin, with most wellness claims resting on mechanistic rationale rather than large RCTs. Injectable NAD+ has found its strongest clinical footing in addiction recovery, where a 10-day IV protocol dropped substance cravings from 5.9 to 0.22 on a 10-point scale in 50 patients [2].
A 398% spike in plasma levels after one six-hour drip. That single data point from a 2019 pilot study [1] turned NAD+ (Nicotinamide Adenine Dinucleotide, CAS 53-84-9) from a biochemistry footnote into one of the most discussed molecules in longevity circles. NAD+ sits at the center of cellular energy metabolism. It shuttles electrons through glycolysis, the tricarboxylic acid cycle, and oxidative phosphorylation to produce ATP. It also feeds three enzyme families that control aging: sirtuins (SIRT1 through SIRT7), PARPs for DNA repair, and CD38, an ectoenzyme whose activity rises with age and is now considered a primary driver of NAD+ decline. Between ages 40 and 60, cellular NAD+ drops roughly 50%. The practical question is whether restoring those levels from the outside actually changes outcomes. For addiction recovery, the answer looks promising. The BR+NAD protocol (500 to 1,500 mg/day IV over 10 days) reduced craving scores from 5.9 to 0.22 in 50 substance use disorder patients [2]. For general wellness and anti-aging, the community runs ahead of the science. Hundreds of threads across r/Nootropics, r/longevity, and r/Peptides consistently report improved energy, reduced brain fog, and better exercise recovery with subcutaneous dosing at 100 to 250 mg twice weekly. A 2024 systematic review [3] confirmed safety across clinical conditions but called the efficacy evidence "heterogeneous." Science has not refuted the wellness case; data simply lags community adoption.
NAD+ is a central metabolic coenzyme in oxidized (NAD+) and reduced (NADH) forms. It passes electrons through three energy-generating pathways: glycolysis, the tricarboxylic acid cycle, and the electron transport chain. Without adequate NAD+, ATP production slows at every step. Beyond energy, NAD+ is the required substrate for sirtuins (SIRT1 through SIRT7), a family of deacetylases that regulate gene expression, mitochondrial biogenesis, and inflammatory signaling. SIRT1 and SIRT3 are the two most studied in longevity research. When NAD+ levels rise, SIRT1-mediated deacetylation of PGC-1alpha increases, promoting new mitochondrial formation and improved oxidative capacity. PARPs (poly-ADP-ribose polymerases) consume NAD+ to repair DNA breaks. After genotoxic stress, PARP1 activation can drain the cellular NAD+ pool rapidly; this is one reason PARP inhibitor cancer drugs work by keeping NAD+ low. Exogenous NAD+ supplementation directly opposes that mechanism. CD38, an ectoenzyme that degrades NAD+, rises with age and is now recognized as a primary cause of age-related NAD+ decline. Direct IV or subcutaneous NAD+ administration bypasses the multi-step enzymatic conversion that oral precursors like NMN and NR require. It also supports the NAD+/NADH ratio in the electron transport chain, reducing electron leak and reactive oxygen species production.
IV NAD+ produces rapid, significant plasma elevation (up to 398% above baseline after 6-hour infusion)[1]. IV addiction recovery protocol (BR+NAD) is the best-supported acute clinical use: PMID 36118157 (n=50) showed craving scores drop from 5.9 to 0.22 on 10-point scale. General anti-aging and wellness claims rest on mechanistic rationale (sirtuin activation, PARP substrate replenishment, mitochondrial biogenesis) with limited controlled human trial data. 2024 systematic review [3] confirms safety across clinical conditions but efficacy evidence remains heterogeneous.
PMID 36118157: BR+NAD IV protocol in 50 SUD patients, 2022
Most wellness/anti-aging trials are small (n<50), unblinded, or lack placebo control. IV plasma half-life is ~30–45 min: functional benefit persistence is mechanistically supported but not yet quantified with RCT rigor. No head-to-head SubQ vs IV outcomes RCT exists. Long-term safety of chronic SubQ administration unstudied.
Highly positive overall. Energy uplift and mid-afternoon crash elimination are the most consistently reported benefits. Brain fog clearance, especially in long COVID and chronic fatigue contexts, is frequently cited. IV sessions praised for acute "reset" feeling. SubQ valued for practical, lower-cost maintenance between IV sessions.
Science and community converge on IV NAD+ for addiction/acute loading protocols. Community wellness use (SubQ maintenance, anti-aging) is driven by mechanistic extrapolation and self-reported outcomes rather than RCT evidence. Science has not refuted the wellness use case: data simply lags community adoption.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mg | 2x/week |
| Moderate | 250mg | 2x/week |
| Aggressive | 500mg | 3x/week |
Your 500 mg vial with 5 mL bacteriostatic water gives you 100 mg/mL. At 100 mg per dose, that's 1.0 mL (100 units on a U-100 insulin syringe), so one vial covers 5 doses. If you're running 250 mg doses, reconstitute with 2 mL instead: that gives 250 mg/mL, and each dose is 1.0 mL. Trying to pull 2.5 mL for a 250 mg dose from a standard 5 mL reconstitution is impractical for a single subcutaneous site. Inject slowly. Thirty to sixty seconds minimum. The sting is the number one complaint in every forum thread, and speed is almost always the cause. Warm the syringe in your palm for a minute before injecting. Morning dosing is the standard; some users report sleep disruption with evening administration. One thing most beginners miss: cloudiness or any visible precipitate means discard the vial. NAD+ degrades with heat and agitation. Add the water slowly down the vial wall and swirl gently. Never shake it.
Some protocols run continuously at maintenance doses. Higher-dose IV protocols are typically done in short bursts (3-5 days). Subcutaneous dosing can be sustained longer with periodic breaks.
NAD+ functions as a substrate and signaling molecule, not a receptor agonist: receptor desensitization is not the primary concern. Cycling is recommended due to: (1) absence of long-term chronic-use safety data in humans; (2) theoretical concern about sustained supraphysiologic PARP and CD38 activation and downstream inflammatory signaling effects; (3) clinical convention from IV protocols, which use short burst dosing. The 8-on/2-off structure aligns with peptides.ts cycling protocol and community consensus. Continuous low-dose maintenance (100 mg 1×/week) is used by some without cycling breaks but lacks safety evidence for this approach.
Or use the universal Peptide Calculator for any peptide.
Expected: Improved energy, reduced brain fog, better sleep quality; cognitive benefits more consistent by week 4–6
Monitor: No formal monitoring required at this dose for healthy adults; diabetics should track fasting glucose
Gather your supplies: 500 mg NAD+ lyophilized vial, bacteriostatic water, alcohol swabs, 27 to 31 gauge insulin syringe (U-100).
Reconstitute: add 5 mL bacteriostatic water slowly down the inside wall of the vial. Swirl gently until fully dissolved. This gives 100 mg/mL. For higher concentration, use 2 mL water for 250 mg/mL.
Draw your dose: for 100 mg, pull to the 100 unit mark (1.0 mL). For 250 mg from a 250 mg/mL reconstitution, pull to the 100 unit mark (1.0 mL). For 50 mg titration dose, pull to the 50 unit mark (0.5 mL from 100 mg/mL solution).
Abdomen (2 inches from the navel) or upper outer thigh. Rotate sites each injection.
Pinch the skin, insert the needle at a 45 to 90 degree angle, and inject slowly over 30 to 60 seconds. Slow injection is the single most important factor for reducing the sting.
Do not recap.
Store the reconstituted vial refrigerated at 2 to 8 degrees Celsius. Use within 28 days. Never freeze reconstituted NAD+.
Dose twice weekly for the beginner protocol (100 mg) or twice weekly for intermediate (250 mg).
Higher peak plasma concentrations achievable (398% above baseline, PMID 31572171); faster onset; more pronounced subjective response; IV plasma t½ ~30–45 min so effect duration tied to infusion duration
Standard clinic IV dose 250–500 mg over 2–4 hours; addiction protocol 500–1,500 mg/day over 5–10 hours. Rate-dependent side effects (nausea, flushing) managed by slowing infusion.
Slower absorption through adipose tissue; lower, sustained delivery profile; near-100% bioavailability (bypasses GI first-pass metabolism); fewer acute side effects than IV
Volume limit ~1 mL per injection site; doses >100 mg require more concentrated reconstitution (2 mL BAC water instead of 5 mL) or split injections. 500 mg vial + 5 mL BAC water = 100 mg/mL; + 2 mL = 250 mg/mL.
Faster absorption than SubQ; similar bioavailability; not studied head-to-head with SubQ for NAD+
Community use documented but less prevalent than SubQ; deltoid or gluteal injection typical; same dosing as SubQ generally applied
Oral NAD+ has poor bioavailability; oral precursors NMN/NR undergo multi-step enzymatic conversion and achieve lower peak plasma NAD+ elevations vs injection. 2026 study (PMID 41704678) showed similar tolerability between IV NAD+ and IV NR but did not compare SubQ vs oral outcomes
Cost-effective for long-term maintenance (~$50–$150/month vs $150–$350/month compounded SubQ); many users bridge between injectable cycles with oral NMN 500 mg or NR 300–1,000 mg/day. NOT equivalent for addiction recovery protocols.
IV push given immediately after NAD+ infusion at most wellness clinics; synergistic antioxidant support alongside NAD+-mediated energy restoration
IV push 200–600 mg glutathione after NAD+ infusion; SubQ co-injection at separate site for home use
Mitochondrial synergy: SS-31 targets inner membrane cardiolipin while NAD+ restores upstream electron transport chain substrate; complementary mechanisms in longevity stacks
SS-31 5–20 mg SubQ daily + NAD+ 100 mg SubQ 2×/week
Longevity stack: Epithalon activates telomerase while NAD+ supports DNA repair via sirtuin/PARP pathways; used together in anti-aging protocols
Cycle sequentially or concurrent: Epithalon 5–10 mg/day × 10–20 days, then NAD+ SubQ maintenance
Energy + body composition stack popular in biohacker community; GH secretagogue + NAD+ provides energy, recovery, and mitochondrial support synergy
Ipamorelin 100–200 mcg SubQ 2–3×/week + NAD+ 100–250 mg SubQ 2×/week
PARP inhibitors work by depleting cellular NAD+: exogenous NAD+ supplementation directly counteracts their mechanism of action and may reduce efficacy in cancer treatment
Do not combineAlcohol metabolism via alcohol dehydrogenase continuously consumes NAD+; heavy concurrent use blunts therapeutic benefit by depleting the NAD+ pool being restored
Pricing updated 2026-04-09
The most serious safety concern with injectable NAD+ is endotoxin contamination. GenoGenix LLC issued a Class I recall in October 2025 covering their 100 mg/mL and 200 mg/mL NAD+ vials for raised endotoxins; a Class II recall for sterility assurance concerns preceded it in July 2025. Fever or rigors within one to two hours of injection are sentinel signs of endotoxin exposure. Stop immediately, do not reuse the vial, and seek medical evaluation. IV infusion side effects are rate-dependent. Nausea, flushing, chest tightness, and headache occur during the drip and are directly proportional to the infusion speed. Slowing the rate resolves symptoms within minutes in most cases. These are not allergic reactions and do not indicate a defective product. During the BR+NAD addiction protocol (500 to 1,500 mg/day over 5 to 10 hours), these effects are expected and managed by the supervising clinician. Subcutaneous injection stinging is the most common complaint at the home-use level. Injecting slowly over 30 to 60 seconds, warming the solution to room temperature, and using a 27 to 31 gauge insulin syringe all reduce the discomfort. Some injection sites are worse than others; rotating between abdomen and upper thigh helps. Published side effect data beyond the above is limited. The 2024 systematic review [3] confirmed safety across clinical conditions but noted the total number of rigorously studied humans remains small. Most wellness and anti-aging trials have fewer than 50 participants, and many lack placebo controls. Theoretical concerns exist around sustained supraphysiologic PARP and CD38 activation at high chronic doses. No hepatotoxicity has appeared in trials, but safety data for long-term subcutaneous use does not exist. Liver enzymes (ALT and AST) should be checked at baseline and at 8 weeks for anyone dosing at 250 mg or above per session. NAD+ may support rapidly dividing cells. No data exists on its effects in active cancer or a history of malignancy. It should not be combined with PARP inhibitor drugs (olaparib, niraparib, rucaparib), as exogenous NAD+ directly counteracts their mechanism of action. Pregnancy and breastfeeding are absolute contraindications since no safety data exists for injectable NAD+ in those populations.
Verify NAD+ dosing and safety with a second opinion
Active FDA recall history: GenoGenix LLC issued a Class I recall (October 2025) of 100 mg/mL and 200 mg/mL NAD+ injectable vials for elevated endotoxins; a Class II recall (July 2025) for sterility assurance concerns preceded this. Compounded NAD+ is not FDA-approved, and NAD+ is particularly susceptible to endotoxin contamination given high compounding demand and production volume in the sector.
| Test | When | Target |
|---|---|---|
| Liver enzymes (ALT, AST, GGT) | Baseline before starting; at 8 weeks for doses ≥250 mg/session | ALT <40 U/L, AST <40 U/L (reference lab ranges) |
| Fasting glucose / HbA1c | Baseline and at 8 weeks for diabetics or pre-diabetics | Per individual clinical targets |
| Blood pressure and heart rate | During every IV infusion session | BP <140/90 mmHg; HR 60–100 bpm during infusion |
| Post-injection endotoxin reaction screening | First 2 hours after injection with each new vial batch | — |
High-dose NAD+ drives PARP and sirtuin activity; theoretical hepatic load at sustained supraphysiologic doses; no established hepatotoxicity in trials but safety data is limited
NAD+ influences glucose metabolism through SIRT1/AMPK pathways; diabetics on insulin or sulfonylureas should monitor for additive glucose-lowering effect
IV NAD+ at high infusion rates may cause transient hemodynamic changes; elevated cardiovascular risk warrants monitoring
Active 2025 recall history for NAD+ injectable products; endotoxin reactions (fever >38°C, rigors, chills) occur within 1–2 hours of contaminated injection
Immediate increase in plasma NAD+ levels (up to 398% above baseline after 6-hour infusion). Some users report improved mental clarity and energy within hours. Nausea, flushing, or chest tightness may occur during infusion.
Transition to subcutaneous injections. Injection site stinging is common but manageable with slow administration. Early reports of improved sleep quality and reduced brain fog.
Sustained energy improvements and better exercise recovery. Cognitive benefits become more consistent. Cellular NAD+ pools are being replenished through ongoing supplementation.
Full benefits are realized including improved mitochondrial function, steady energy levels, and enhanced mental performance. Users in addiction recovery protocols often report reduced cravings at this stage.
Lower-frequency dosing (1-2x/week) to maintain elevated NAD+ levels. Periodic IV booster sessions every 1-3 months are used in some longevity protocols. Benefits are sustained with consistent use.
Day 1 through 3 (IV loading session): Plasma NAD+ can spike to 398% above baseline during a six-hour IV infusion [1]. Many users report a "clean" energy uplift and improved mental clarity within hours of the session. Nausea, flushing, and chest tightness are common during the drip and directly tied to infusion speed; slowing the rate resolves them within minutes. Weeks 1 through 2 (SubQ maintenance start): The injection sting dominates the early experience. Slow administration over 30 to 60 seconds makes it manageable. Improved sleep quality is one of the first benefits users notice, often within the first week or two. Some report reduced brain fog during this window. Cellular NAD+ pools are beginning to replenish; sirtuin and PARP activity increases at the tissue level. Weeks 3 through 6: Energy improvements become more consistent and the mid-afternoon crash most users complain about tends to disappear. Exercise recovery speeds up noticeably. Cognitive benefits get more reliable rather than intermittent. Side effects typically diminish as injection technique improves. Weeks 7 through 12: This is where the full protocol payoff arrives. Mental performance, steady energy, and physical recovery all hit their peak according to community reports. Users in addiction recovery protocols report sustained craving reduction at this stage. Sirtuin-mediated deacetylation of PGC-1alpha is driving mitochondrial biogenesis; PARP-mediated DNA repair efficiency has improved with sustained NAD+ availability. Ongoing maintenance and off weeks: NAD+ levels drift back toward baseline during the two-week break. Some functional benefits persist due to epigenetic changes from sirtuin activation, but substrate-dependent enzymatic activity wanes. Many users run continuous low-dose maintenance at 100 mg once weekly. Others stick to strict 8-on, 2-off cycling. Quarterly IV booster sessions at a clinic are common in longevity protocols.
Plasma NAD+ up to 398% above baseline after 6-hour IV infusion (PMID 31572171); rapid tissue uptake; plasma clearance t½ ~30–45 min so functional levels maintained during multi-hour infusion
Many users report improved mental clarity and elevated mood within hours of IV session; energy uplift described as "clean": not stimulant-like
Cellular NAD+ pools begin replenishment; sirtuin and PARP activity increases; mitochondrial biogenesis markers upregulated
Injection site sting is the dominant early experience; improved sleep quality frequently noted in week 1–2; some report reduced brain fog
Sustained elevation of tissue NAD+ levels with consistent dosing; improved NAD+/NADH ratio supports oxidative phosphorylation efficiency
Energy improvements become more consistent; exercise recovery noticeably faster; mid-afternoon energy crash eliminated for most users; cognitive benefits more reliable
Maximal sirtuin-mediated deacetylation effects; PGC-1α upregulation supports mitochondrial biogenesis; PARP-mediated DNA repair efficiency improved
Peak subjective benefit period; improved mental performance, steady energy, and enhanced physical recovery all reported; addiction recovery users report sustained craving reduction
NAD+ levels return toward baseline during off weeks; functional benefits partially persist due to epigenetic changes (sirtuin-mediated) but substrate-dependent enzymatic benefits wane
Some users run continuous low-dose (100 mg 1×/week); others prefer strict 8-on/2-off cycling; quarterly IV booster used in longevity clinic protocols
Source: Estimated 2-4 hours based on IV infusion metabolome study showing rapid clearance and conversion to metabolites (PMID 31572171)
Loading the interactive decay curve.
NAD+ is not FDA-approved as a therapeutic drug. It is available through compounding pharmacies (both 503A and 503B facilities) as a research compound. The FDA has not approved any NAD+ injectable product for anti-aging, wellness, or addiction treatment indications as of April 2026. Compounded NAD+ carries documented quality risk. The 2025 GenoGenix Class I recall for raised endotoxins in injectable NAD+ vials is a concrete example. Sourcing from an FDA-registered 503B outsourcing facility with a current Certificate of Analysis showing endotoxin and sterility testing is the minimum standard for safety. NAD+ is not on the WADA prohibited list as of 2026 and is not a controlled substance. IV NAD+ protocols for addiction treatment operate in a clinical gray area, offered at specialized wellness and detox clinics without FDA clearance for the indication. This content is for research and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any injectable compound.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
